Compare LYTS & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYTS | RAPP |
|---|---|---|
| Founded | 1976 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 700.9M | 1.2B |
| IPO Year | N/A | 2024 |
| Metric | LYTS | RAPP |
|---|---|---|
| Price | $19.19 | $30.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $27.50 | ★ $47.80 |
| AVG Volume (30 Days) | 156.1K | ★ 361.1K |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 2.57 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $592,531,000.00 | N/A |
| Revenue This Year | $6.26 | N/A |
| Revenue Next Year | $7.45 | N/A |
| P/E Ratio | $24.07 | ★ N/A |
| Revenue Growth | ★ 22.35 | N/A |
| 52 Week Low | $13.77 | $6.43 |
| 52 Week High | $25.50 | $42.27 |
| Indicator | LYTS | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 62.22 |
| Support Level | $18.72 | $27.81 |
| Resistance Level | $19.01 | $31.00 |
| Average True Range (ATR) | 0.45 | 1.84 |
| MACD | 0.29 | 0.11 |
| Stochastic Oscillator | 83.26 | 83.09 |
LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.